by Chinese Academy of Sciences

Number of areas providing free or subsidized HPV vaccination. Credit: Cancer Biology & Medicine (2024). DOI: 10.20892/j.issn.2095-3941.2023.0432

As the fourth most commonly diagnosed cancer among women worldwide, cervical cancer places a significant burden on low and middle-income countries. Although China reports lower incidence and mortality rates compared to the global average, the stark contrast in mortality rates with developed nations like the U.S. and the U.K. underscores the urgent need for enhanced prevention strategies.

A perspective published in Cancer Biology & Medicine provides an in-depth look at the escalating rates of cervical cancer in China, particularly highlighting the rise in rural areas.

This critical research emphasizes the effectiveness of the HPV vaccine in combating cervical cancer and addresses challenges such as vaccine supply constraints, socioeconomic barriers, and vaccine hesitancy.

Researchers analyzed data reflecting the effectiveness of the HPV vaccine, which has proven to be a critical tool in reducing cancer rates. However, the introduction of the vaccine in China was delayed compared to other countries, affecting overall vaccination coverage.

The study also evaluates the impact of China's adoption of the WHO's "90-70-90" strategy—aiming for high vaccination, screening, and treatment rates by 2030. The research outlines the urgent need for a multi-faceted approach that includes boosting vaccine supply, expanding screening programs, and enhancing treatment facilities to address the geographic and economic diversity of the Chinese population.

Dr. Youlin Qiao, the corresponding author of the study, stated, "Our research underscores the critical need for comprehensive cervical cancer control strategies that are tailored to China's diverse socioeconomic landscape. Achieving the World Health Organization's (WHO) elimination targets not only requires robust vaccination programs but also widespread screening and effective treatment methodologies."

This pivotal study not only outlines the current challenges in cervical cancer prevention in China but also charts a strategic path forward to potentially eradicate this disease as a public health issue. With continued efforts and international collaboration, China is poised to meet the WHO's elimination targets within the next decade, signaling a significant leap forward in global health security.

More information: Huijiao Yan et al, Cervical cancer prevention in China: where are we now, and what's next?, Cancer Biology & Medicine (2024). DOI: 10.20892/j.issn.2095-3941.2023.0432

Provided by Chinese Academy of Sciences